<DOC>
	<DOC>NCT00790400</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.</brief_summary>
	<brief_title>Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Angiomyolipoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male or Female 18 years or older Clinically definite diagnosis of Tuberous Sclerosis Complex according to the modified Gomez criteria or sporadic LAM (biopsyproven or compatible chest CT scan) Clinically definite diagnosis of renal angiomyolipoma At least one Angiomyolipoma of â‰¥ 3 cm in its longest diameter using CT or MRI Females of child bearing potential must use birth control and have documentation of negative pregnancy test Written informed consent according to local guidelines Recent heart attack, cardiac related chest pain or stroke Severely impaired lung function Bleeding related to angiomyolipoma or embolization during 6 months prior to randomization Clinically significant chylous ascites Clinically significant hematological or hepatic abnormality Severe liver dysfunction Severe kidney dysfunction Pregnancy or breast feeding Current infection History of organ transplant Surgery within two months prior to study enrollment Prior therapy with a medication in the same class as Everolimus Recent use of an investigational drug Bleeding diathesis or on oral antivitamin K medication Uncontrolled high cholesterol Uncontrolled diabetes HIV Inability to attend scheduled clinic visits Patients with metal implants thus prohibiting MRI evaluations Angiomyolipoma which requires surgery at the time of randomization History of malignancy Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Angiomyolipoma</keyword>
	<keyword>AML</keyword>
	<keyword>Tuberous Sclerosis Complex</keyword>
	<keyword>TSC</keyword>
	<keyword>mTOR</keyword>
	<keyword>RAD001</keyword>
	<keyword>Mammalian Target of Rapamycin</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>SEGA</keyword>
	<keyword>Subependymal Giant Cell Astrocytoma</keyword>
	<keyword>Seizures</keyword>
	<keyword>Tuberous sclerosis complex (TSC)</keyword>
	<keyword>Tuberous sclerosis</keyword>
	<keyword>benign tumors of brain</keyword>
	<keyword>kidney</keyword>
	<keyword>heart</keyword>
	<keyword>eyes</keyword>
	<keyword>lungs</keyword>
	<keyword>skinTSC1</keyword>
	<keyword>TSC2</keyword>
	<keyword>hamaratin</keyword>
	<keyword>tuberin, tumor growth suppressors</keyword>
	<keyword>gyri</keyword>
	<keyword>tubers</keyword>
	<keyword>Sporadic Lymphangioleiomyomatosis.</keyword>
	<keyword>Lymphangioleiomyomatosis (LAM)</keyword>
	<keyword>rare lung disease</keyword>
</DOC>